PL2465492T3 - Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P) - Google Patents

Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)

Info

Publication number
PL2465492T3
PL2465492T3 PL12155251T PL12155251T PL2465492T3 PL 2465492 T3 PL2465492 T3 PL 2465492T3 PL 12155251 T PL12155251 T PL 12155251T PL 12155251 T PL12155251 T PL 12155251T PL 2465492 T3 PL2465492 T3 PL 2465492T3
Authority
PL
Poland
Prior art keywords
sphingosine
sip
phosphate
compositions
receptor modulators
Prior art date
Application number
PL12155251T
Other languages
English (en)
Inventor
Colleen Ruegger
Michael AMBÜHL
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2465492(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2465492T3 publication Critical patent/PL2465492T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
PL12155251T 2007-10-12 2008-10-09 Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P) PL2465492T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
EP12155251.7A EP2465492B1 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine I phosphate (sip) receptor modulators
EP08838495A EP2209493A2 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Publications (1)

Publication Number Publication Date
PL2465492T3 true PL2465492T3 (pl) 2015-11-30

Family

ID=40032615

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12155251T PL2465492T3 (pl) 2007-10-12 2008-10-09 Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
PL15173766T PL2952177T3 (pl) 2007-10-12 2008-10-09 Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15173766T PL2952177T3 (pl) 2007-10-12 2008-10-09 Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p)

Country Status (33)

Country Link
US (6) US8673918B2 (pl)
EP (7) EP2952177B1 (pl)
JP (2) JP6034000B2 (pl)
KR (3) KR101600098B1 (pl)
CN (1) CN101820916A (pl)
AR (1) AR068986A1 (pl)
AU (1) AU2008310846C1 (pl)
BR (1) BRPI0818161B8 (pl)
CA (2) CA2925175A1 (pl)
CL (1) CL2008003003A1 (pl)
CO (1) CO6270342A2 (pl)
DK (1) DK2952177T3 (pl)
EC (1) ECSP10010169A (pl)
ES (2) ES2864671T3 (pl)
HK (1) HK1213768A1 (pl)
HR (1) HRP20150838T1 (pl)
HU (2) HUE053835T2 (pl)
IL (3) IL204514B (pl)
JO (2) JOP20080436B1 (pl)
MA (1) MA31799B1 (pl)
MX (1) MX337152B (pl)
MY (1) MY159358A (pl)
NZ (1) NZ600355A (pl)
PE (2) PE20130309A1 (pl)
PL (2) PL2465492T3 (pl)
PT (2) PT2952177T (pl)
RU (1) RU2010118457A (pl)
SG (2) SG187458A1 (pl)
SI (2) SI2952177T1 (pl)
TN (1) TN2010000136A1 (pl)
TW (1) TW200927142A (pl)
WO (1) WO2009048993A2 (pl)
ZA (1) ZA201001819B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
CA2733508A1 (en) 2008-08-18 2010-02-25 David Leppert Compounds for the treatment of peripheral neuropathies
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
MA32981B1 (fr) * 2008-12-22 2012-01-02 Novartis Ag Regime posologique pour un agoniste du recepteur s1p
CA2797042A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
WO2011131370A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Melt-granulated fingolimod
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
AU2012204835B2 (en) * 2011-01-07 2015-07-09 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
EP2739272A1 (en) 2011-08-01 2014-06-11 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
CA2852142A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
US20160128951A1 (en) 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
US20170027906A1 (en) * 2014-04-10 2017-02-02 Philippe Michel Rene Bouillot Immunosuppressant formulation
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US10786461B2 (en) * 2014-11-17 2020-09-29 Context Biopharma Inc. Onapristone extended-release compositions and methods
JP2018502168A (ja) * 2015-01-20 2018-01-25 ハンダ ファーマシューティカルズ エルエルシー 安定な固体フィンゴリモド剤形
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
WO2016175230A1 (ja) * 2015-04-28 2016-11-03 アステラス製薬株式会社 経口投与用医薬組成物
PE20181175A1 (es) 2015-08-12 2018-07-20 Incyte Corp Sales de un inhibidor de lsd1
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
CA3000186A1 (en) * 2015-10-02 2017-04-06 Mylan Inc. Stable formulations of fingolimod
MA44725A (fr) * 2016-04-22 2019-02-27 Incyte Corp Formulations d'un inhibiteur de lsd1
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
KR20220142376A (ko) * 2021-04-14 2022-10-21 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
ATE211726T1 (de) 1994-08-22 2002-01-15 Welfide Corp Benzolderivate und deren medizinische verwendung
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
EP0990440B1 (en) 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
CN1137086C (zh) 1997-04-04 2004-02-04 三菱制药株式会社 2-氨基丙烷-1,3-二醇化合物、其作为医药的用途及其合成中间体
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
DK1431284T3 (da) 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
DE60235900D1 (de) 2001-09-27 2010-05-20 Kyorin Seiyaku Kk Osuppressivum
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
JP4571497B2 (ja) 2002-09-19 2010-10-27 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
ES2360394T3 (es) 2003-02-18 2011-06-03 Kyorin Pharmaceutical Co., Ltd. Derivados de ácido aminofosfónico, sales de adición de los mismos y moduladores del receptor s1p.
EP2769713A1 (en) 2003-04-08 2014-08-27 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
PE20050158A1 (es) 2003-05-19 2005-05-12 Irm Llc Compuestos inmunosupresores y composiciones
JP2007523858A (ja) 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット 血管透過性およびアポトーシスの阻害方法
PL1660449T3 (pl) 2003-08-28 2010-05-31 Novartis Ag Pochodne aminopropanolu
CA2539033C (en) 2003-09-12 2013-03-05 Neuronova Ab Treatment of disease or injury of the nervous system with fty720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (en) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
ES2748432T3 (es) * 2006-09-26 2020-03-16 Novartis Ag Composiciones farmacéuticas que comprenden un modulador de S1P

Also Published As

Publication number Publication date
PE20090799A1 (es) 2009-07-20
WO2009048993A2 (en) 2009-04-16
EP3733161A1 (en) 2020-11-04
NZ600355A (en) 2013-02-22
KR20160025633A (ko) 2016-03-08
BRPI0818161B8 (pt) 2021-05-25
US20170151195A1 (en) 2017-06-01
SI2952177T1 (sl) 2021-07-30
KR101710845B1 (ko) 2017-02-27
ES2864671T3 (es) 2021-10-14
IL255737A (en) 2018-01-31
CN101820916A (zh) 2010-09-01
US20160296481A1 (en) 2016-10-13
ES2545361T3 (es) 2015-09-10
PE20130309A1 (es) 2013-03-30
US9399066B2 (en) 2016-07-26
EP2465492A1 (en) 2012-06-20
TN2010000136A1 (en) 2011-09-26
US20150165046A1 (en) 2015-06-18
PT2465492E (pt) 2015-10-15
IL204514B (en) 2018-01-31
US20100267675A1 (en) 2010-10-21
AU2008310846C1 (en) 2022-10-06
CA2699788A1 (en) 2009-04-16
BRPI0818161A2 (pt) 2017-05-16
AU2008310846B2 (en) 2012-06-21
EP2465492B1 (en) 2015-07-01
JP2011500583A (ja) 2011-01-06
EP3120833A1 (en) 2017-01-25
HUE053835T2 (hu) 2021-07-28
EP2209493A2 (en) 2010-07-28
ECSP10010169A (es) 2010-06-29
PT2952177T (pt) 2021-04-26
DK2952177T3 (da) 2021-04-26
EP2952177A1 (en) 2015-12-09
KR20100091179A (ko) 2010-08-18
PL2952177T3 (pl) 2021-07-19
KR101600098B1 (ko) 2016-03-04
AU2008310846A1 (en) 2009-04-16
CO6270342A2 (es) 2011-04-20
SI2465492T1 (sl) 2015-12-31
KR20170021904A (ko) 2017-02-28
WO2009048993A3 (en) 2010-05-06
AR068986A1 (es) 2009-12-23
US20140142192A1 (en) 2014-05-22
HK1213768A1 (zh) 2016-07-15
US8673918B2 (en) 2014-03-18
RU2016138157A3 (pl) 2020-02-10
RU2016138157A (ru) 2018-12-13
EP3733162A1 (en) 2020-11-04
JP6034000B2 (ja) 2016-11-30
TW200927142A (en) 2009-07-01
BRPI0818161B1 (pt) 2020-12-22
ZA201001819B (en) 2010-12-29
MA31799B1 (fr) 2010-10-01
CL2008003003A1 (es) 2009-05-15
MY159358A (en) 2016-12-30
IL255737B (en) 2020-10-29
JOP20210187A1 (ar) 2023-01-30
HUE027696T2 (en) 2016-10-28
SG10201800085XA (en) 2018-02-27
JP2015091822A (ja) 2015-05-14
IL277999A (en) 2020-11-30
CA2699788C (en) 2016-06-14
US20170368001A1 (en) 2017-12-28
MX337152B (es) 2016-02-15
HRP20150838T1 (hr) 2015-11-06
SG187458A1 (en) 2013-02-28
JOP20080436B1 (ar) 2023-03-28
RU2010118457A (ru) 2011-11-20
EP2653154A1 (en) 2013-10-23
EP2952177B1 (en) 2021-01-20
MX2010003925A (es) 2010-05-05
CA2925175A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
PL2465492T3 (pl) Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
HK1214758A1 (zh) 用於治療多發硬化症的 受體調節劑
HK1126222A1 (en) Modulators of toll-like receptor 7
EP2344446A4 (en) S1P RECEPTOR MODULATORS
HK1213873A1 (zh) 選擇性的雜環 -磷酸鞘氨醇受體調節劑
GB0701992D0 (en) Grehlin Receptor Modulators
IL204786A0 (en) Benzyl - cycloalkyl sphingosing 1 - phosphate receptor modulators
IL209306A0 (en) Novel modulators of sphingosine phosphate receptors
EP2081575A4 (en) ALLOSTERIC MODULATORS OF THE A1 ADENOSINE RECEPTOR
ZA200806237B (en) Cannibinoid receptor modulators
GB0610311D0 (en) Bisphosphonate formulation